These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 9766447

  • 1. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M, Uharek L, Glass B, Vosskötter W, Dreger P, Schmitz N, Steinmann J.
    Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
    [Abstract] [Full Text] [Related]

  • 2. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M, Uharek L, Glass B, Gaska T, Gassmann W, Mueller-Ruchholtz W.
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [Abstract] [Full Text] [Related]

  • 3. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L, Glass B, Zeis M, Dreger P, Steinmann J, Löffler H, Schmitz N.
    Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
    [Abstract] [Full Text] [Related]

  • 4. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S.
    J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666
    [Abstract] [Full Text] [Related]

  • 5. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L, Reich S, Slavin S.
    Cytokines Cell Mol Ther; 1999 Sep 15; 5(3):145-52. PubMed ID: 10641572
    [Abstract] [Full Text] [Related]

  • 6. Immunotherapeutic aspects of allogeneic peripheral progenitor cells.
    Glass B, Uharek L, Hartung G, Zeis M, Steinmann J, Dreger P, Krönke M, Schmitz N.
    Bone Marrow Transplant; 1998 Jun 15; 21 Suppl 3():S3-8. PubMed ID: 9712483
    [Abstract] [Full Text] [Related]

  • 7. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
    Zeis M, Steinmann J, Petrela E, Hartung G, Schmitz N, Uharek L.
    Bone Marrow Transplant; 2001 Feb 15; 27(3):279-85. PubMed ID: 11277175
    [Abstract] [Full Text] [Related]

  • 8. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD, Drobyski WR, Truitt RL.
    Bone Marrow Transplant; 1993 Apr 15; 11(4):329-36. PubMed ID: 8485480
    [Abstract] [Full Text] [Related]

  • 9. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.
    Uharek L, Glass B, Gaska T, Zeiss M, Gassmann W, Löffler H, Müller-Ruchholtz W.
    Bone Marrow Transplant; 1993 Apr 15; 12 Suppl 3():S57-60. PubMed ID: 8124260
    [Abstract] [Full Text] [Related]

  • 10. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
    Fowler DH, Breglio J, Nagel G, Eckhaus MA, Gress RE.
    J Immunol; 1996 Dec 01; 157(11):4811-21. PubMed ID: 8943383
    [Abstract] [Full Text] [Related]

  • 11. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD, Becker EE, Truitt RL.
    Biol Blood Marrow Transplant; 1999 Dec 01; 5(3):123-32. PubMed ID: 10392958
    [Abstract] [Full Text] [Related]

  • 12. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P, Vourka-Karussis U, Weiss L, Slavin S.
    J Immunol; 1993 Nov 01; 151(9):4803-10. PubMed ID: 8409438
    [Abstract] [Full Text] [Related]

  • 13. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
    Aizawa S, Kamisaku H, Sado T.
    Bone Marrow Transplant; 1995 Oct 01; 16(4):603-9. PubMed ID: 8528179
    [Abstract] [Full Text] [Related]

  • 14. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD, Mori S, Mann S, Savary CA, Mullen CA.
    Cancer Res; 2000 Oct 15; 60(20):5797-802. PubMed ID: 11059776
    [Abstract] [Full Text] [Related]

  • 15. Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia.
    Kloosterman TC, Tielemans MJ, Martens AC, van Bekkum DW, Hagenbeek A.
    Bone Marrow Transplant; 1994 Jul 15; 14(1):15-22. PubMed ID: 7951103
    [Abstract] [Full Text] [Related]

  • 16. Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses.
    Ji YH, Weiss L, Zeira M, Abdul-Hai A, Reich S, Schuger L, Slavin S.
    Bone Marrow Transplant; 2003 Sep 15; 32(5):495-504. PubMed ID: 12942096
    [Abstract] [Full Text] [Related]

  • 17. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
    Taniguchi Y, Yoshihara S, Hoshida Y, Inoue T, Fujioka T, Ikegame K, Kawakami M, Masuda T, Aozasa K, Kawase I, Ogawa H.
    Exp Hematol; 2008 Sep 15; 36(9):1216-25. PubMed ID: 18599183
    [Abstract] [Full Text] [Related]

  • 18. [Study on nonmyeloablative allogeneic bone marrow transplantation in the treatment of L615 leukemia mice].
    Xu KL, Ju JP, Pan XY, Du B, Li ZY, Lu QX.
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul 15; 24(7):372-5. PubMed ID: 12941194
    [Abstract] [Full Text] [Related]

  • 19. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR, Pearson DA, Swenson K, Zhao G, Sachs J, Yang YG, Sykes M.
    Biol Blood Marrow Transplant; 1999 Jul 15; 5(3):133-43. PubMed ID: 10392959
    [Abstract] [Full Text] [Related]

  • 20. Treatment of BCL1 leukemia by transplantation of low density fractions of allogeneic bone marrow and spleen cells.
    Palathumpat V, Holm B, Dejbakhsh-Jones S, Strober S.
    J Immunol; 1992 May 15; 148(10):3319-26. PubMed ID: 1578152
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.